Shah Capital Cuts Novavax Stake To 6.39%, Sells 2.87M Shares At Average Price Of $11.35/Share, Restructures Holdings Into Family Office
- SEC Filing
Stocks · News reference
Transcript: Novavax Q2 2026 Earnings Conference Call
Novavax (NASDAQ:NVAX) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shah Capital Filed To Voluntarily Withdraw Its Registration As An Investment Adviser With SEC, Effective Oct. 16; Shah Capital No Longer Holds Novavax Shares With Purpose Of Influencing Control, Intends To Report On Schedule 13G Going Forward
https://www.sec.gov/Archives/edgar/data/1000694/000139834426018323/xslSCHEDULE_13D_X02/primary_doc.xml
Citigroup Maintains Sell on Novavax, Raises Price Target to $8
Citigroup analyst Geoff Meacham maintains Novavax (NASDAQ:NVAX) with a Sell and raises the price target from $7 to $8.
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.